SOS1
42 programs · 39 companies
Programs
42
Companies
39
Active Trials
32
Targeting SOS1
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | CKDEndometrial Ca | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | ASMCL | |
| Voxacagene | Gilead Sciences | Phase 2/3 | IgAN | |
| SRP-9822 | Sarepta | Phase 3 | BCCCRC | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | CRCPTSD | |
| Zanurapivir | Immunocore | Phase 1 | MesoThymoma | |
| Rilurelsin | Dynavax | Phase 1/2 | MCL | |
| Fixamavacamten | Dynavax | Phase 2 | AMLEwing Sarcoma | |
| Mirirasimod | Ipsen | Phase 2 | RCCCrohn's | |
| EME-6317 | Emerald Health | Approved | MGCrohn's | |
| MD-IIT-285 | MD Anderson | Phase 1 | Angelman | |
| CHI-3786 | Chinook (Novartis) | Phase 2 | LNDravet | |
| Capifutibatinib | Vesalius Ther | Phase 2/3 | CSUMM | |
| Pexainavolisib | Asklepios Bio | Approved | GACTCL | |
| Talacapivasertib | Aerovate Ther | Phase 1/2 | RettLN | |
| Cevifutibatinib | Iridex | Phase 3 | Atopic DermHeart Failure | |
| Tiracagene | Cidara Therapeutics | Phase 3 | RSVSCD | |
| CNT-6977 | Connect Biopharma | Preclinical | PSPBladder Ca | |
| 269-7185 | Henlius | Preclinical | Ewing SarcomaPNH | |
| CAR-9528 | Caris Life Sci | Preclinical | PompeRA | |
| Zoritapinarof | InveniAI | Phase 1 | LGSAtopic Derm | |
| Niralemzoparlimab | Generate Bio | Phase 2/3 | HNSCCHemophilia A | |
| Zoricilimab | Lenz Ther | Phase 2 | MCCIgAN | |
| LOG-8406 | LogicBio (closed) | Phase 3 | CF | |
| Sovazasiran | LogicBio (closed) | Phase 1/2 | HCCSchizophrenia | |
| Cevirapivir | Oxford BioMedica | Approved | HCC | |
| NIC-5654 | Nichi-Iko | Phase 1/2 | MDDDMD | |
| Nidalemzoparlimab | Chiome Bio | Phase 1 | PsoriasisOCD | |
| Zoriratamab | LG Chem Life | Approved | CMLSchizophrenia | |
| CHI-2221 | Chiesi | Phase 3 | AML | |
| Mirisacituzumab | NTC Pharma | NDA/BLA | EpilepsyBreast Ca | |
| ALK-3993 | Alkem Labs | Phase 3 | MigraineNarcolepsy | |
| BIO-9702 | Biolab Pharma | Phase 1 | FSGSMigraine | |
| Tezerelsin | Blau Farmaceutica | Phase 1/2 | Crohn'sMCC | |
| Olpasacituzumab | Probiomed | Approved | ALLBCC | |
| KLB-9971 | Kalbe Farma | Phase 1/2 | DMD | |
| ROY-IIT-404 | Royal Marsden | Approved | SCLC | |
| HOS-IIT-510 | Hospital Israelita Einstein | Preclinical | Prostate Ca | |
| ZEN-8892 | Zentiva | Phase 2/3 | Atopic DermRett | |
| Elralucimab | Zoetis | Phase 1/2 | ThymomaAS | |
| ZTS-820 | Zoetis | NDA/BLA | DMDCrohn's | |
| Cevisertib | Santen Pharma | Phase 2/3 | Thymoma |